Randomized evaluation of the beneficial effect of Livact in patients with heart failure complicated by hypoalbuminemia

Randomized evaluation of the beneficial effect of Livact in patients with heart failure complicated by hypoalbuminemia - Livact Heart Failure Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004488

Enrollment

Registered

2010-11-08

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure patients complicated by hypoalbuminemia

Interventions

Intervention Conventional therapy plus Livact 12g t.i.d. 4 weeks or until discharge Control Conventional therapy only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Hospitalized patients due to exacerbation of heart failure 2) Hypoalbuminemia in two discrete blood test during hospitalization 3) over 20 years old

Exclusion criteria

Exclusion criteria: 1) Renal dysfunction (BUN over 40mg/dl or Cre over 2.0mg/dl 2) Nephrotic syndrome, or urine protein over 3+ 3) HbA1c over 8.0% 4) Liver cirrhosis 5) Patients with malignancy 6) Patients with abnormal branched-chain amino acid metabolism 7) Ventricular arrhythmia 8) Patients who need ventilator support. 9) Severe infectious disease 10) Patients who are enrolled in another clinical trial

Design outcomes

Primary

Measure	Time frame
Serum albumine Cardiothoracic ratio (CTR)	—

Secondary

Measure	Time frame
Duration of admission, Hospitalization cost, Amount of food intake, Performance status, BNP, Amino acid fraction, Racio of mercapto albumin, Left ventricular ejection fraction	—

Countries

Japan

Contacts

Public ContactMasafumi Watanabe

University of Tokyo Hospital Department of Cardiovascular Medicine

masafumi-tky@umin.net03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026